Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31391115 | 0.83 | MAP4K4 (0.43) | MAP4K4DOT1LPIK3CDTNK2POLRMT | |
| SCHEMBL27315074 | 0.80 | MAP4K4 (0.41) | MAP4K4PIK3CDTNK2ACVRL1 | |
| SCHEMBL19377633 | 0.78 | AXL (0.39) | MAP4K4DOT1LPIK3CDACVRL1 | |
| SCHEMBL19429619 | 0.77 | CSNK2A2 (0.38) | MAP4K4DOT1LTNK2POLRMTACVRL1 | |
| SCHEMBL16011257 | 0.77 | ACVRL1 (0.46) | MAP4K4DOT1LPOLRMTDYRK1AACVRL1 | |
| SCHEMBL22627061 | 0.77 | ACVRL1 (0.51) | MAP4K4PIK3CDACVRL1 | |
| SCHEMBL19377694 | 0.77 | PIK3CD (0.42) | MAP4K4PIK3CD | |
| SCHEMBL16011256 | 0.77 | ACVRL1 (0.46) | MAP4K4DOT1LPOLRMTDYRK1AACVRL1 | |
| SCHEMBL14488031 | 0.75 | MAP4K4 (0.37) | MAP4K4DOT1LPIK3CDTNK2POLRMT | |
| SCHEMBL20960065 | 0.75 | MAP4K4 (0.37) | MAP4K4DOT1LPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | MAP4K4 693/4885DOT1L 2111/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.